Klein Lawrence Otto 4
Research Summary
AI-generated summary
Oruka (ORKA) CEO Klein Lawrence Otto Sells 1,729 Shares
What Happened Klein Lawrence Otto, CEO of Oruka Therapeutics, sold 1,729 shares on 2026-03-16 at $41.30 per share, resulting in proceeds of approximately $71,408. The Form 4 was filed on 2026-03-17. This was a sale (S) and not a purchase or option exercise.
Key Details
- Transaction date and price: 2026-03-16 — 1,729 shares sold at $41.30 each.
- Total proceeds: about $71,408.
- Shares owned after transaction: not disclosed in the provided filing details.
- Footnote: The sale was effected under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations arising from RSU vesting (Footnote F1).
- Filing timeliness: Report filed the next day (2026-03-17), which is timely for a Form 4 filing.
Context Sell-to-cover transactions are routine tax-withholding sales tied to the vesting of restricted stock units and generally reflect tax obligations rather than an independent trading decision. This filing documents the mechanics of that withholding sale rather than a discretionary divestiture by the insider.